{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:02:12Z","timestamp":1789596132449,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.humpath.2026.106260","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:45:49Z","timestamp":1789119949000},"page":"106260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Detection of androgen receptor (AR) splice variants across diverse prostatic and non-prostatic tumor types using the TruSight Oncology 500 (TSO500) assay"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5138-824X","authenticated-orcid":false,"given":"Beth A.","family":"Pitel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surendra","family":"Dasari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber L.","family":"Pryzbylski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7643-2836","authenticated-orcid":false,"given":"Daniel S.","family":"Childs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7115-7554","authenticated-orcid":false,"given":"Dijana","family":"Poljak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Keeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0424-7572","authenticated-orcid":false,"given":"Katherine","family":"Geiersbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4880-7172","authenticated-orcid":false,"given":"Peter C.","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0319-0239","authenticated-orcid":false,"given":"Jacob J.","family":"Orme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth I.","family":"Heath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9256-4484","authenticated-orcid":false,"given":"Rumeal D.","family":"Whaley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin J.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori A.","family":"Erickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Cheville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussam","family":"Al-Kateb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin R.","family":"Kipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin C.","family":"Halling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel S.","family":"Antonarakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5163-6955","authenticated-orcid":false,"given":"Sounak","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2026.106260_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112563","article-title":"AR splicing variants and resistance to AR targeting agents","volume":"13","author":"Kanayama","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.humpath.2026.106260_bib2","doi-asserted-by":"crossref","first-page":"19736","DOI":"10.1074\/jbc.M112.352930","article-title":"Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal","volume":"287","author":"Chan","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.humpath.2026.106260_bib3","doi-asserted-by":"crossref","DOI":"10.1172\/JCI168649","article-title":"Androgen receptor splice variants drive castration-resistant prostate cancer metastasis by activating distinct transcriptional programs","volume":"134","author":"Han","year":"2024","journal-title":"J Clin Investig"},{"key":"10.1016\/j.humpath.2026.106260_bib4","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.eururo.2020.03.044","article-title":"Combined cell-free DNA and RNA profiling of the androgen receptor: clinical utility of a novel multianalyte liquid biopsy assay for metastatic prostate cancer","volume":"78","author":"Fettke","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.humpath.2026.106260_bib5","article-title":"Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making","volume":"2017","author":"Abida","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.humpath.2026.106260_bib6","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s41391-024-00814-2","article-title":"Genomic attributes of prostate cancer across primary and metastatic noncastrate and castrate resistant disease states: a next generation sequencing study of 183 patients","volume":"28","author":"Dasari","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.humpath.2026.106260_bib7","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The molecular taxonomy of primary prostate cancer","volume":"163","author":"Cancer Genome Atlas Research","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.humpath.2026.106260_bib8","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ajur.2020.01.001","article-title":"Regulation of androgen receptor variants in prostate cancer","volume":"7","author":"Zhu","year":"2020","journal-title":"Asian J Urol"},{"key":"10.1016\/j.humpath.2026.106260_bib9","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2026.106260_bib10","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamaoncol.2015.1341","article-title":"Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer","volume":"1","author":"Antonarakis","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.humpath.2026.106260_bib11","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.eururo.2019.04.006","article-title":"Clinical utility of circulating tumour cell androgen receptor splice Variant-7 status in metastatic castration-resistant prostate cancer","volume":"76","author":"Sharp","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.humpath.2026.106260_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/cells13010104","article-title":"Therapeutic approaches to targeting androgen receptor splice variants","volume":"13","author":"Daniels","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.humpath.2026.106260_bib13","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/s41379-021-00924-5","article-title":"Androgen receptor splice variant-7 in breast cancer: clinical and pathologic correlations","volume":"35","author":"Ferguson","year":"2022","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2026.106260_bib14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.humpath.2018.09.009","article-title":"Expression pattern of androgen receptor and AR-V7 in androgen-deprivation therapy-naive salivary duct carcinomas","volume":"84","author":"Yang","year":"2019","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2026.106260_bib15","doi-asserted-by":"crossref","first-page":"7322","DOI":"10.1002\/cam4.2602","article-title":"Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling","volume":"8","author":"Gargano","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.humpath.2026.106260_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11082215","article-title":"Beyond prostate cancer: an androgen receptor splice variant expression in multiple malignancies, non-cancer pathologies, and development","volume":"11","author":"Katleba","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.humpath.2026.106260_bib17","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jmoldx.2025.01.002","article-title":"Clinical validation of the TruSight oncology 500 assay for the detection and reporting of pan-cancer biomarkers","volume":"27","author":"Al-Kateb","year":"2025","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.humpath.2026.106260_bib18","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jmoldx.2025.12.001","article-title":"Development and clinical validation of OncCNV: a pipeline for comprehensive genome-wide analysis of oncogene amplifications, homozygous deletions, and biallelic inactivation of tumor suppressor genes using the TruSight oncology 500 kit","volume":"28","author":"Smoley","year":"2026","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.humpath.2026.106260_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.mayocp.2025.11.003","article-title":"Utility of next-generation sequencing in renal Neoplasia, including tumors with clear cytoplasm and rare phenotypes (ELOC\/MITF alterations and mismatch repair deficiency)","author":"McCarthy","year":"2026","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.humpath.2026.106260_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines8100422","article-title":"The androgen receptor in prostate cancer: effect of structure, ligands and spliced variants on therapy","volume":"8","author":"Messner","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.humpath.2026.106260_bib21","first-page":"CGE23","article-title":"CGE23-072: the frequency of androgen receptor splice variant 7 (AR-V7) in solid tumors","volume":"21","author":"Gatalica","year":"2023","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.humpath.2026.106260_bib22","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1177\/10668969241253197","article-title":"NTRK3-Rearranged prostatic acinar adenocarcinoma: report of a patient and review of the literature","volume":"33","author":"Whaley","year":"2025","journal-title":"Int J Surg Pathol"},{"key":"10.1016\/j.humpath.2026.106260_bib23","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.eururo.2021.01.037","article-title":"Androgen receptor splice variant 7 predicts shorter response in patients with metastatic hormone-sensitive prostate cancer receiving androgen deprivation therapy","volume":"79","author":"Li","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.humpath.2026.106260_bib24","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1080\/0284186X.2019.1637540","article-title":"AR-V7 expression in circulating tumor cells as a potential prognostic marker in metastatic hormone-sensitive prostate cancer","volume":"58","author":"Josefsson","year":"2019","journal-title":"Acta Oncol"},{"key":"10.1016\/j.humpath.2026.106260_bib25","doi-asserted-by":"crossref","DOI":"10.1172\/JCI198193","article-title":"Androgen receptor splice variant 7 expression levels distinguish AR-mutated from nonmutated metastatic castration-resistant prostate cancers","volume":"136","author":"Paschalis","year":"2026","journal-title":"J Clin Investig"},{"key":"10.1016\/j.humpath.2026.106260_bib26","doi-asserted-by":"crossref","first-page":"10503","DOI":"10.1021\/acs.jmedchem.5c01250","article-title":"RIPTACs for precision cancer therapy: a novel modality with the inspiration of HLD-0915 as the first candidate in clinical trials","volume":"68","author":"Ma","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.humpath.2026.106260_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104500","article-title":"Targeting androgen receptor and the variants by an orally bioavailable proteolysis targeting Chimeras compound in castration resistant prostate cancer","volume":"90","author":"Hung","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.humpath.2026.106260_bib28","first-page":"263","article-title":"PROTACs for prostate cancer","volume":"20","author":"Stone","year":"2023","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.humpath.2026.106260_bib29","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.chembiol.2024.07.005","article-title":"Regulated induced proximity targeting chimeras-RIPTACs-A heterobifunctional small molecule strategy for cancer selective therapies","volume":"31","author":"Raina","year":"2024","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.humpath.2026.106260_bib30","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS5115","article-title":"An oral prostate cancer RIPTAC therapeutic in phase 1 for metastatic castrate resistant prostate cancer (mCRPC)","volume":"43","author":"Kayser-Bricker","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2026.106260_bib31","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1200\/JCO.2023.41.6_suppl.184","article-title":"An oral androgen receptor RIPTAC for prostate cancer","volume":"41","author":"Raina","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2026.106260_bib32","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41391-020-0214-6","article-title":"Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer","volume":"23","author":"Gupta","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.humpath.2026.106260_bib33","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1186\/s12885-024-13165-x","article-title":"Prognostic role of Androgen Receptor splice variant 7 (AR-V7) in the pathogenesis of breast cancer","volume":"24","author":"Srivastava","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.humpath.2026.106260_bib34","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2016.71.3495","article-title":"Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer","volume":"36","author":"Traina","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2026.106260_bib35","article-title":"Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: trial results and insights into \"ARness\"","volume":"5","author":"Lim","year":"2024","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.humpath.2026.106260_bib36","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1038\/s41379-020-0576-2","article-title":"Molecular patterns in salivary duct carcinoma identify prognostic subgroups","volume":"33","author":"Mueller","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2026.106260_bib37","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1200\/JCO.22.00229","article-title":"Phase II study of enzalutamide for patients with androgen receptor-positive salivary gland cancers (Alliance A091404)","volume":"40","author":"Ho","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2026.106260_bib38","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ajoc.2016.11.003","article-title":"Androgen receptor-positive ductal adenocarcinoma of the nasolacrimal duct: a case report","volume":"5","author":"Park","year":"2017","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.humpath.2026.106260_bib39","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1097\/PAI.0000000000000313","article-title":"An androgen receptor-positive carcinoma of the lacrimal drainage system resembling salivary duct carcinoma: case report and review of the literature","volume":"24","author":"Rahimi","year":"2016","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.humpath.2026.106260_bib40","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13048-018-0384-1","article-title":"The molecular mechanism of ovarian granulosa cell tumors","volume":"11","author":"Li","year":"2018","journal-title":"J Ovarian Res"},{"key":"10.1016\/j.humpath.2026.106260_bib41","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/00000478-198408000-00002","article-title":"Juvenile granulosa cell tumor of the ovary. A clinicopathological analysis of 125 cases","volume":"8","author":"Young","year":"1984","journal-title":"Am J Surg Pathol"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817726002297?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817726002297?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:06:46Z","timestamp":1789592806000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817726002297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":41,"alternative-id":["S0046817726002297"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2026.106260","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Detection of androgen receptor (AR) splice variants across diverse prostatic and non-prostatic tumor types using the TruSight Oncology 500 (TSO500) assay","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2026.106260","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106260"}}